Skip to main content

Bohlin Garen G

In the past year, 1 open-market sale filing worth $323.5K and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$323.5K
1 filing
Net
−$323.5K
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Bohlin Garen G as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

COLL Collegium Pharmaceutical, Inc

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 13, 2026 (view filing)May 112 daysBohlin Garen GDirectorSSale−8.70K$37.18−$323.5K−12.3%62.3K after
May 16, 2024 (view filing)May 142 daysBohlin Garen GDirectorSSale−29.0K$32.30−$936.2K−39.3%44.8K after

KPTI Karyopharm Therapeutics Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 12, 2023 (view filing)Sep 12Same dayBohlin Garen GDirectorPPurchase+41.1K$1.22+$50.2K+1,028.5%45.1K after